

China to export macrolide antibiotic to India

10 September 2014 | News | By BioSpectrum Bureau



Singapore: China-based Tianyin Pharmaceutical's API operation Jiangchuan Macrolide Facility has initiated the application process for the import certificate in India via India's Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare.

The initiative is triggered by a surge in the orders by API users from India for JCM's Azithromycin API products and intermediates.

Further testing and improvement on quality, purity, stereochemistry, stability in compliance with the international standards of Azithromycin API have been conducted at JCM following an increasing amount of orders from both domestic and international buyers.

Previously, JCM had been receiving orders to manufacture one of the major intermediates of Azithromycin, Azithromycin amine (Azi Amine) at a competitive international price. And the increasing demand for Azithromycin API necessitates the application for certificate of import. TPI will provide updates on the development of the Azithromycin export on a quarterly basis.

Azithromycin (Azi) is a macrolide antibiotic related to erythromycin. It is used primarily to treat various bacterial infections caused by respiratory pathogens, such as Aerobic gram-positive microorganisms and Aerobic gram-negative microorganisms. Azi prevents bacterial cells from manufacturing specific proteins necessary for their survival. Azi is rapidly absorbed and is widely distributed to tissues and becomes concentrated in cells. Peak plasma concentrations are achieved within 2 to 3 hours. Azi Amine is a close intermediate of Azi and enjoys competitive pricing trends amongst various

derivatives of Azi related products.